Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AstraZeneca

< Previous 1 2 3 4 5 6 7 8 Next >
AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) significantly improved progression-free survival in DESTINY-Breast03 head-to-head trial vs. trastuzumab emtansine (T-DM1) in patients with HER2
From AstraZeneca
Via Business Wire
Tickers AZN
SAPHNELO (anifrolumab) Approved in the US for Moderate to Severe Systemic Lupus Erythematosus
From AstraZeneca
Via Business Wire
Tickers AZN
BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older
From AstraZeneca
Via Business Wire
Tickers AZN
Tezepelumab Regulatory Submission Accepted and Granted FDA Priority Review in the US for the Treatment of Patients with Asthma
From AstraZeneca
Via Business Wire
Tickers AZN
Phase III pivotal trial of once weekly exenatide in adolescents aged 10–17 shows benefit for the treatment of type 2 diabetes
From AstraZeneca
Via Business Wire
Tickers AZN
CALQUENCE Demonstrated Fewer Incidences of Atrial Fibrillation Versus Ibrutinib in Previously Treated Patients With Chronic Lymphocytic Leukemia and Sustained Patient Benefit at Four Years in the Front-line Setting
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Lung Cancer With 43% Of Patients Surviving Five Years
From AstraZeneca
Via Business Wire
Tickers AZN
LYNPARZA® (olaparib) reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca ASCO 2021 Data Support Ambition to Revolutionize Cancer Outcomes by Treating Earlier and Transforming the Patient Experience
From AstraZeneca
Via Business Wire
Tickers AZN
New FASENRA® Data From the MELTEMI Extension Trial Confirm Long-Term Safety and Efficacy in Severe Eosinophilic Asthma for up to Five Years
From AstraZeneca
Via Business Wire
Tickers AZN
New Tezepelumab Data Continue to Strengthen Profile for a Broad Population of Severe Asthma Patients
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI and tremelimumab With Chemotherapy Demonstrated Overall Survival Benefit in POSEIDON Trial for 1st-line Stage IV Non-small Cell Lung Cancer
From AstraZeneca
Via Business Wire
Tickers AZN
FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type 2 Diabetes
From AstraZeneca
Via Business Wire
Tickers AZN
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.